Psoriatic arthritis

Questions discussed in this category

How do you approach managing nausea and GI side effects when initiating methotrexate?

2 Answers available

How do you approach management of patients with psoriatic arthritis who have significant improvement in skin disease, but ongoing inflammatory arthritis despite multiple DMARDs and/or biologics?

1 Answer available

Do you avoid the use of hydroxychloroquine in patients with psoriasis and/or psoriatic arthritis?

2 Answers available

Are there circumstances when you may consider imaging enthesitis in patients with psoriatic arthritis?

What imaging modality would be most helpful?

2 Answers available

Do you offer LDRT for psoriatic arthritis, rheumatoid arthritis, or polymyalgia rheumatica or fibromyalgia?

2 Answers available

How do you approach immunosuppression in patients with a positive Interferon Gamma Release Assay and prior intravesicular BCG treatment for bladder cancer?

Assuming no symptoms of TB, should patients be treated for latent TB prior to starting TNF inhibitors or other immunosuppressive agents?

1 Answer available

Would you consider a biologic or JAK inhibitor to manage active PsA in a patient on chronic antibiotic therapy if they had previously failed all conventional DMARDs (including apremilast)?

Patient is on antibiotics for chronic spinal hardware infection.

1 Answer available

Do you find MRI helpful to differentiate early erosive OA from psoriatic arthritis when early X-ray changes in both conditions may be hard to distinguish?

1 Answer available

Would you consider using a JAK inhibitor in combination with an IL 23 inhibitor in cases of severe psoriasis, psoriatic arthritis, or axial spondyloarthritis that is refractory to multiple biologic DMARDs?

2 Answers available

Are there any concerns utilizing apremilast for psoriatic arthritis in patients who are also taking roflumilast for COPD?

1 Answer available

What is your approach to using apremilast for psoriatic arthritis in patients with history of depression?

1 Answer available

How long would you recommend that a patient continues guselkumab prior to deciding that the therapy is not effective?

In contrast to TNF inhibitors for psoriatic arthritis, which seem to peak and maintain response percentages, the DISCOVER-2 Trial (McInnes et al., PMI...

4 Answers available

How do you interpret treatment response in the DISCOVER-2 Trial when patients were allowed to remain on up to 10mg of prednisone equivalent for disease control while on guselkumab?

In clinical practice continued steroid dependence is often seen as a reason to switch therapy and providers can be especially hesitant to use systemic...

3 Answers available

Where in the sequence of biologics would you consider guselkumab for patients with active psoriatic arthritis despite standard DMARD therapy?

Based on the results of the DISCOVER-2 Trial (McInnes et al., PMID 34719872), should guselkumab be used prior to anti-TNF therapy in these patients?

3 Answers available

How do you manage psoriatic arthritis in patients who are planning to start treatment with checkpoint inhibitors for underlying malignancy?

2 Answers available

What has been your experience using apremilast to treat mild to moderate psoriatic arthritis not controlled with NSAIDs?

1 Answer available

Are there any known contraindications for IL-23 use in patients with psoriatic arthritis and CKD or ESRD?

1 Answer available

What disease activity measures do you find helpful in clinical practice for psoriatic arthritis/peripheral spondyloarthritis?

1 Answer available

Would you continue TNFi for inflammatory arthritis if the patient develops a solid organ malignancy while on that therapy?

1 Answer available

Would you use an IL-17 inhibitor for a psoriatic arthritis patient with inactive inflammatory bowel disease?

1 Answer available

Would you use an anti-IL 17 over an anti-TNFa as your first line biologic in psoriatic arthritis?

Have the SPIRIT H2H and EXCEED data changed your practice?

1 Answer available

What is the preferred DMARD in active spondyloarthropathy with psoriasis and sacroiliitis features in the setting of treated hepatitis C with negative viral load?

In patients refractory to NSAIDs and sulfasalazine

1 Answer available

What are some strategies for radiographically differentiating between erosions secondary to erosive osteoarthritis versus psoriatic arthritis involving the DIP joints?

1 Answer available

How do you differentiate between axial psoriatic arthritis and axial spondylitis with psoriasis, and is it important to distinguish between these two conditions from a prognostic and treatment perspective?

1 Answer available

Papers discussed in this category

Arthritis Rheumatol, 2019 Jan

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.

Ann. Rheum. Dis., 2019 Sep 28

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.

Lancet,

Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.

Arthritis & rheumatology (Hoboken, N.J.), 2016-05

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis.

Arthritis Rheumatol, 2019 Oct

2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.

Rheumatology (Oxford),

Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis?

Rheumatology (Oxford),

Axial disease in psoriatic arthritis.

Clin. Exp. Rheumatol., 2016 Dec 13

Clinical and genetic associations of radiographic sacroiliitis and its different patterns in psoriatic arthritis.

Lancet, 2015 Oct 01

Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial.

J Rheumatol Suppl,

GRAPPA 2018 Project Report.

Nat Rev Rheumatol,

Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison.

Rheumatology (Oxford),

Treatment guidelines in psoriatic arthritis.

Ann Rheum Dis, 2015 Dec 07

European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.

J Med Imaging Radiat Oncol,

Gull-wing deformity: Osteoarthritis.

J Ultrason, 2016 Mar 29

Diagnostic imaging of psoriatic arthritis. Part I: etiopathogenesis, classifications and radiographic features.

Annals of the rheumatic diseases, 2017-04

International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials.

Arthritis Care Res (Hoboken), 2018 Aug

Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis: Results From a Tight-Control Clinical Trial and an Observational Cohort.

Arthritis Care Res (Hoboken),

Measuring Outcomes in Psoriatic Arthritis.

Journal of clinical medicine, 2022 Apr 21

Ultrasound of the Heel Improves Diagnosis-Tender Entheses in the Heel Region Rarely Corresponds to Inflammatory Enthesitis in Patients with Peripheral Spondyloarthritis.

Clinical and experimental rheumatology, 2020 Feb 11

Assessment of enthesis in patients with psoriatic arthritis and fibromyalgia using clinical examination and ultrasound.

Journal of clinical medicine, 2021 Dec 29

Use of Ultrasonography to Discriminate Psoriatic Arthritis from Fibromyalgia: A Post-Hoc Analysis of the ULISSE Study.

Clinical and experimental rheumatology, 2022 Mar 01

Ultrasound evaluation of the Achilles enthesis in inflammatory and non-inflammatory processes: a systematic review and meta-analysis.

Curr Med Chem,

Targeting IL-17 and IL-23 in Immune Mediated Renal Disease.

Pathology, 2017 Mar 11

The role of interleukin-17A in the pathogenesis of kidney diseases.

Arthritis Care Res (Hoboken), 2019 Jan

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.

Arthritis Rheumatol, 2022 Feb 07

Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis.

Annals of internal medicine, 2018-01-16

Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review.

J Immunother Cancer,

Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.

Rheumatology (Oxford), 2014 Sep 16

Differentiation between osteoarthritis and psoriatic arthritis: implications for pathogenesis and treatment in the biologic therapy era.

The Journal of rheumatology, 2012-01

Combination biologic treatment of refractory psoriasis and psoriatic arthritis.

JAAD Case Rep, 2019 Oct 10

Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritis.

Clinical rheumatology, 1988 Sep

Treatment of psoriatic arthritis with sulphasalazine: a one year open study.

Journal of the American Academy of Dermatology, 1987 Apr

Gold therapy and its indications in dermatology. A review.

Journal of the American Academy of Dermatology, 2020 May 19

Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment.

Annals of the rheumatic diseases, 2018-09

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.

Arthritis & rheumatology (Hoboken, N.J.), 2019-02

Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis.

RMD open, 2020 Feb

Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials.

The New England journal of medicine, 2014 Jun 05

Once-weekly dalbavancin versus daily conventional therapy for skin infection.

Trials, 2022 Sep 05

Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial.

Related Topics